BOUL Stock Overview
Boule Diagnostics AB (publ), ein Diagnostikunternehmen, entwickelt, fertigt und vertreibt Instrumente und Verbrauchsmaterialien für die Blutdiagnostik.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr9.84 |
| 52 Week High | kr13.00 |
| 52 Week Low | kr8.66 |
| Beta | 0.52 |
| 1 Month Change | -5.02% |
| 3 Month Change | -17.31% |
| 1 Year Change | -17.03% |
| 3 Year Change | -85.66% |
| 5 Year Change | -83.87% |
| Change since IPO | -16.08% |
Recent News & Updates
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20
Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Recent updates
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively
Jan 30Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?
Jan 14How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?
Dec 28Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Dec 10What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?
Nov 22Shareholder Returns
| BOUL | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -0.4% | 1.1% | -1.3% |
| 1Y | -17.0% | -8.2% | 11.7% |
Rendite im Vergleich zur Industrie: BOUL unter dem Niveau der Branche Swedish Medical Equipment , die im vergangenen Jahr eine Rendite von -10.8% erzielte.
Rendite vs. Markt: BOUL hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 5.8 erzielte.
Price Volatility
| BOUL volatility | |
|---|---|
| BOUL Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stabiler Aktienkurs: BOULDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: BOULDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 200 | Jesper Soderqvist | https://www.boule.com |
Boule Diagnostics AB (publ), ein Diagnostikunternehmen, entwickelt, fertigt und vertreibt Instrumente und Verbrauchsmaterialien für die Blutdiagnostik. Das Unternehmen bietet Hämatologie-Analysegeräte, Reagenzien, Blutkontrollen und -kalibratoren sowie Reagenzienrotoren und Reinigungsprodukte unter den Marken Swelab, Medonic, CDS und Quintus an; außerdem veterinärmedizinische Hämatologie- und klinisch-chemische Analyse- und Diagnosesysteme unter der Marke Exigo. Das Unternehmen vertreibt seine Produkte direkt in Schweden und den Vereinigten Staaten sowie über internationale Vertriebshändler.
Boule Diagnostics AB (publ) Fundamentals Summary
| BOUL fundamental statistics | |
|---|---|
| Market cap | kr382.12m |
| Earnings (TTM) | kr25.00m |
| Revenue (TTM) | kr571.30m |
15.3x
P/E Ratio0.7x
P/S RatioIs BOUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOUL income statement (TTM) | |
|---|---|
| Revenue | kr571.30m |
| Cost of Revenue | kr321.60m |
| Gross Profit | kr249.70m |
| Other Expenses | kr224.70m |
| Earnings | kr25.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 16, 2024
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 43.71% |
| Net Profit Margin | 4.38% |
| Debt/Equity Ratio | 29.9% |
How did BOUL perform over the long term?
See historical performance and comparison